Inactive Instrument

Insiders Hemispherx BioPharma, Inc Nyse

Equities

US42366C1036

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 10	AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	CI
Apr. 02	Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AIM ImmunoTech Says Delaware Court Rules in Its Favor, Deeming Activist Group's Board Nominations 'Invalid'	Dec. 29	MT
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board?s Determination that Activist Group?s Nominations Are Invalid	Dec. 29	CI
Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation	23-08-28	CI
AIM ImmunoTech Rejects Director Nomination Notice from Ted D. Kellner	23-08-23	CI
Ted D. Kellner Nominates Candidates to the Board of AIM ImmunoTech	23-08-07	CI
AIM ImmunoTech Inc. Appoints W. Neal Burnette as Chairman of Its Scientific Advisory Board	23-04-12	CI
AIM ImmunoTech Inc. Appoints Nancy K. Bryan as Member of Board of Director	23-03-30	CI
AIM ImmunoTech Inc. Names Robert Dickey IV as CFO	23-03-06	CI
AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer	22-12-12	CI
AIM ImmunoTech Says Delaware Court of Chancery Denies Activist Group's Board Nomination Bid	22-10-31	MT
Delaware Court Declines to Declare Jonathan Jorgl’s Nominations Valid	22-10-31	CI
Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation	22-08-16	CI
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer	22-07-21	AQ
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data	22-07-20	GL
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data	22-07-20	AQ
AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data	22-07-20	CI
AIM ImmunoTech Names Robert Dickey as CFO	22-03-03	MT
AIM ImmunoTech : CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc	21-08-17	AQ
AIM ImmunoTech : CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.	21-08-16	AQ
AIM ImmunoTech, Inc. Appoints Peter W. Rodino, III as Chief Operating Officer	19-10-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Hemispherx BioPharma, Inc Nyse

Equities

US42366C1036

Insiders

Filters